The efficacy and safety of sirolimus‐based graft‐versus‐host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta‐analysis of randomized controlled trials

Citations Over TimeTop 14% of 2015 papers

Abstract

BACKGROUND The efficacy and safety of sirolimus (SIR)‐based graft‐versus‐host disease (GVHD) prophylaxis in patients who were subjected to allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain to be clarified; this meta‐analysis was conducted to evaluate these factors. STUDY DESIGN AND METHODS Data from original research were obtained from PubMed, Embase, and Cochrane central register of controlled trials databases. Randomized controlled trials (RCTs) evaluating the efficacy of SIR‐based prophylaxis in allo‐HSCT were included. The risk ratio (RR), with a 95% confidence interval (CI), was used to pool data. The random effects model was used, irrespective of the presence or absence of heterogeneity. RESULTS Five RCTs were included in the meta‐analysis. SIR was observed to significantly decrease the incidence of Grade II to IV acute GVHD (aGVHD; RR, 0.65; 95% CI, 0.47‐0.89). However, the incidence of Grade III to IV aGVHD and chronic GVHD was not decreased (RR, 0.91; 95% CI, 0.59‐1.40; RR, 1.04; 95% CI, 0.88‐1.23, respectively). An analysis of the toxic effects of SIR revealed that SIR effected a significant increase in the incidence of sinusoidal obstructive syndrome (RR, 2.24; 95% CI, 1.26‐4.01), while that of thrombotic microangiopathy was not significantly increased (RR, 2.48; 95% CI, 0.87‐7.06). Moreover, SIR did not improve event‐free survival and overall survival (RR, 0.97; 95% CI, 0.85‐1.10; and RR, 0.92; 95% CI, 0.82‐1.02, respectively). CONCLUSION This meta‐analysis indicated that the SIR‐based regimen is an effective and safe alternative prophylaxis strategy for GVHD.

Related Papers

• → Sirolimus May Promote Thrombotic Microangiopathy(2003)48 cited
• → Topical sirolimus for management of refractory oral chronic graft‐versus‐host disease(2020)2 cited
• From understanding the molecular basis of Graft-versus-Host Disease (GvHD), to new diagnostic tools and innovative treatments for improving the management of patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT)(2014)
• PREDICTIVITY OF TEAR PARAMETERS IN THE ONSET OF OCULAR GRAFT VERSUS HOST DISEASE (GVHD) DRY EYE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).(2013)
• → Oral Graft-Versus-Host Disease(2022)